pb1046
Peptideexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2016 (NCT02808585)
Timeline
Indications
Studied for
- Coronavirus · Phase 2
- COVID-19 · Phase 2
- Cytokine Release Syndrome · Phase 2
- Heart Diseases · Phase 2
- Heart Failure · Phase 2
- Lung Diseases · Phase 2
- Pneumonia · Phase 2
- Pulmonary Arterial Hypertension · Phase 2
- Pulmonary Edema · Phase 2
- Respiratory Distress Syndrome · Phase 2
- Respiratory Insufficiency · Phase 2
- SARS-CoV-2 · Phase 2
Mechanism of action
VIPR1 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- pb1046
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04433546 | Phase 2 | Jun 26, 2020 | PhaseBio Pharmaceuticals Inc. |
| NCT03795428 | Phase 2 | Apr 10, 2019 | PhaseBio Pharmaceuticals Inc. |
| NCT03556020 | Phase 2 | Jul 15, 2018 | PhaseBio Pharmaceuticals Inc. |
| NCT03315507 | Phase 1 | Oct 20, 2017 | PhaseBio Pharmaceuticals Inc. |
| NCT02808585 | Phase 2 | Jun 1, 2016 | PhaseBio Pharmaceuticals Inc. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| PhaseBio Pharmaceuticals Inc. | For profit | 5 | 5 | 2 | 2016 |
1 organizations
Page 1 / 1